Sequential high-dose methotrexate and fluorouracil combined with doxorubicin--a step ahead in the treatment of advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cooperative Group - PubMed

Clinical Trial

Sequential high-dose methotrexate and fluorouracil combined with doxorubicin--a step ahead in the treatment of advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cooperative Group

J A Wils et al. J Clin Oncol. 1991 May.

Abstract

In a prospective phase III multicenter trial, 213 patients with advanced measurable or nonmeasurable gastric cancer were randomized to receive methotrexate (MTX), fluorouracil (5-FU), and Adriamycin (doxorubicin; Farmitalia Carlo Erba, Milan, Italy) (FAMTX) or 5-FU, Adriamycin, and mitomycin (FAM). The results show a significantly superior response rate (41% v 9% [P less than .0001]), and survival (median, 42 weeks v 29 weeks [P = .004]) for FAMTX. There was a cumulative thrombocytopenia in FAM and not in FAMTX. The FAMTX protocol should be the reference treatment in future clinical trials that seek to improve the therapeutic outcome in advanced gastric cancer.

Comment in

• Chemotherapy in advanced gastric carcinoma.

  Adenis A, Bonneterre J. Adenis A, et al. J Clin Oncol. 1991 Nov;9(11):2077-8. doi: 10.1200/JCO.1991.9.11.2077. J Clin Oncol. 1991. PMID: 1941068 No abstract available.

• Standard chemotherapy for gastric carcinoma: is it a myth?

  Ajani JA. Ajani JA. J Clin Oncol. 2000 Dec 1;18(23):4001-3. doi: 10.1200/JCO.2000.18.23.4001. J Clin Oncol. 2000. PMID: 11099333 No abstract available.

• Standard chemotherapy for gastric carcinoma: is it a myth?

  Tebbutt NC, Norman A, Hill M, Cunningham D. Tebbutt NC, et al. J Clin Oncol. 2001 May 15;19(10):2765-7. doi: 10.1200/JCO.2001.19.10.2765. J Clin Oncol. 2001. PMID: 11352971 No abstract available.

Similar articles

• Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: A trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group.

  Vanhoefer U, Rougier P, Wilke H, Ducreux MP, Lacave AJ, Van Cutsem E, Planker M, Santos JG, Piedbois P, Paillot B, Bodenstein H, Schmoll HJ, Bleiberg H, Nordlinger B, Couvreur ML, Baron B, Wils JA. Vanhoefer U, et al. J Clin Oncol. 2000 Jul;18(14):2648-57. doi: 10.1200/JCO.2000.18.14.2648. J Clin Oncol. 2000. PMID: 10894863 Clinical Trial.

• An EORTC Gastrointestinal Group evaluation of the combination of sequential methotrexate and 5-fluorouracil, combined with adriamycin in advanced measurable gastric cancer.

  Wils J, Bleiberg H, Dalesio O, Blijham G, Mulder N, Planting A, Splinter T, Duez N. Wils J, et al. J Clin Oncol. 1986 Dec;4(12):1799-803. doi: 10.1200/JCO.1986.4.12.1799. J Clin Oncol. 1986. PMID: 3783204

• [Recent advances in chemotherapy for advanced gastric cancer: from the standpoint of survival advantages].

  Ohtsu A, Yoshida S, Miyata Y, Shimada Y. Ohtsu A, et al. Gan To Kagaku Ryoho. 1995 Mar;22(4):444-50. Gan To Kagaku Ryoho. 1995. PMID: 7887636 Review. Japanese.

• The treatment of advanced gastric cancer.

  Wils J. Wils J. Semin Oncol. 1996 Jun;23(3):397-406. Semin Oncol. 1996. PMID: 8658224 Review.

Cited by

• Docetaxel and oxaliplatin combination in second-line treatment of patients with advanced gastric cancer.

  Barone C, Basso M, Schinzari G, Pozzo C, Trigila N, D'Argento E, Quirino M, Astone A, Cassano A. Barone C, et al. Gastric Cancer. 2007;10(2):104-11. doi: 10.1007/s10120-007-0415-x. Epub 2007 Jun 25. Gastric Cancer. 2007. PMID: 17577620 Clinical Trial.

• Phase I/II study of S-1 combined with paclitaxel in patients with unresectable and/or recurrent advanced gastric cancer.

  Mochiki E, Ohno T, Kamiyama Y, Aihara R, Haga N, Ojima H, Nakamura J, Ohsawa H, Nakabayashi T, Takeuchi K, Asao T, Kuwano H; North Kanto Gastric Cancer Study Group. Mochiki E, et al. Br J Cancer. 2006 Dec 18;95(12):1642-7. doi: 10.1038/sj.bjc.6603497. Epub 2006 Nov 28. Br J Cancer. 2006. PMID: 17133268 Free PMC article. Clinical Trial.

• S-1 in the treatment of advanced and recurrent gastric cancer: current state and future prospects.

  Takahashi I, Kakeji Y, Emi Y, Sakurai M, Yonemura Y, Kimura Y, Maehara Y. Takahashi I, et al. Gastric Cancer. 2003;6 Suppl 1:28-33. doi: 10.1007/s10120-003-0228-5. Gastric Cancer. 2003. PMID: 12775017

• Management of carcinomas of the upper gastrointestinal tract.

  Ellis P, Cunningham D. Ellis P, et al. BMJ. 1994 Mar 26;308(6932):834-8. doi: 10.1136/bmj.308.6932.834. BMJ. 1994. PMID: 8167493 Free PMC article. Review.

• Prognostic factors in resectable gastric cancer: results of EORTC study no. 40813 on FAM adjuvant chemotherapy.

  Lise M, Nitti D, Marchet A, Sahmoud T, Duez N, Fornasiero A, dos Santos JG, Labianca R, Lasser P, Gignoux M. Lise M, et al. Ann Surg Oncol. 1995 Nov;2(6):495-501. doi: 10.1007/BF02307082. Ann Surg Oncol. 1995. PMID: 8591079 Clinical Trial.

Publication types

MeSH terms

Substances

Supplementary concepts

LinkOut - more resources

• Full Text Sources

  • Atypon
  • Ovid Technologies, Inc.

• Other Literature Sources

  • The Lens - Patent Citations Database

• Medical

  • MedlinePlus Health Information